Reported about 5 hours ago
Eli Lilly has raised its full-year profit and revenue forecast, driven by strong demand for its weight-loss and diabetes medications, Zepbound and Mounjaro, leading to a third-quarter earnings beat. The company's shares rose 6% in premarket trading as it aims to compete with Novo Nordisk in a burgeoning $150 billion weight-loss drug market. Despite potential U.S. price negotiations, Lilly anticipates earning between $23.00 and $23.70 per share this year, up from the previous forecast of $21.75 to $23.00.
Source: YAHOO